Literature DB >> 18573286

Rapid fluorescent assay for screening drugs on Leishmania amastigotes.

Orly Shimony1, Charles L Jaffe.   

Abstract

A rapid fluorescent viability assay employing alamarBlue was optimized for use with Leishmania axenic amastigotes, the stage of the parasite responsible for disease pathology. The activity of two protein kinase inhibitors, Staurosporine and H-89, as well as Amphotericin B, on promastigotes and amastigotes of Leishmania donovani and Leishmania tropica was compared. Both protein kinase inhibitors inhibited promastigote growth at lower concentrations than amastigotes, while the GI(50) for Amphotericin B on both stages was similar. This assay only requires a limited number of axenic amastigotes (50,000 cells/well) and can be used to rapidly screen large chemical or natural product libraries for activity against amastigotes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573286     DOI: 10.1016/j.mimet.2008.05.026

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  28 in total

1.  From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

Authors:  Emilie Durieu; Eric Prina; Olivier Leclercq; Nassima Oumata; Nicolas Gaboriaud-Kolar; Konstantina Vougogiannopoulou; Nathalie Aulner; Audrey Defontaine; Joo Hwan No; Sandrine Ruchaud; Alexios-Leandros Skaltsounis; Hervé Galons; Gerald F Späth; Laurent Meijer; Najma Rachidi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species.

Authors:  Daniel B Liarte; Silvane M F Murta
Journal:  Parasitol Res       Date:  2010-04-07       Impact factor: 2.289

3.  Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.

Authors:  Aiman Abu Ammar; Abed Nasereddin; Suheir Ereqat; Mary Dan-Goor; Charles L Jaffe; Eyal Zussman; Ziad Abdeen
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

4.  Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Authors:  Najma Rachidi; Jean François Taly; Emilie Durieu; Olivier Leclercq; Nathalie Aulner; Eric Prina; Pascale Pescher; Cedric Notredame; Laurent Meijer; Gerald F Späth
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

5.  Identification of the molecular attributes required for aminoglycoside activity against Leishmania.

Authors:  Moran Shalev; Jiro Kondo; Dmitry Kopelyanskiy; Charles L Jaffe; Noam Adir; Timor Baasov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

6.  Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.

Authors:  Tana Bowling; Luke Mercer; Robert Don; Robert Jacobs; Bakela Nare
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-03-03       Impact factor: 4.077

7.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

8.  Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives.

Authors:  Juan Carlos Villalobos-Rocha; Luvia Sánchez-Torres; Benjamín Nogueda-Torres; Aldo Segura-Cabrera; Carlos A García-Pérez; Virgilio Bocanegra-García; Isidro Palos; Antonio Monge; Gildardo Rivera
Journal:  Parasitol Res       Date:  2014-04-02       Impact factor: 2.289

9.  Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

Authors:  Manu De Rycker; Irene Hallyburton; John Thomas; Lorna Campbell; Susan Wyllie; Dhananjay Joshi; Scott Cameron; Ian H Gilbert; Paul G Wyatt; Julie A Frearson; Alan H Fairlamb; David W Gray
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

10.  Antileishmanial macrolides from ant-associated Streptomyces sp. ISID311.

Authors:  Humberto E Ortega; Vitor B Lourenzon; Marc G Chevrette; Leonardo L G Ferreira; René F Ramos Alvarenga; Weilan G P Melo; Tiago Venâncio; Cameron R Currie; Adriano D Andricopulo; Tim S Bugni; Mônica T Pupo
Journal:  Bioorg Med Chem       Date:  2021-01-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.